Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T
Department of Biotechnology, University of Turku, Finland.
Clin Chem. 1995 Aug;41(8 Pt 1):1115-20.
We developed a simple one-step dual-label immunoassay for simultaneous measurement of the free, noncomplexed form of prostate-specific antigen (PSA) and total PSA. The assay is based on time-resolved fluorescence and includes a stable fluorescent chelate of Eu to label a monoclonal antibody (mAb) that detects only free PSA, whereas a second mAb labeled with a fluorescent chelate of Tb provides equimolar detection of both free PSA and PSA complexed to alpha 1-antichymotrypsin. A third mAb on a solid phase captures the free and complexed forms of PSA in an equimolar fashion. The simultaneous measurement of the free-to-total PSA ratio (F/T) with the one-step dual assay is not sensitive to variations in the sample volume. The discrimination between benign prostatic hyperplasia and prostate cancer patients, i.e., the area under the receiver-operating characteristic curve, increased from 0.64 (total PSA assay) to 0.78 and 0.81 when the F/T ratio was measured with single and dual assays, respectively.
我们开发了一种简单的一步双标记免疫测定法,用于同时测量游离的、非复合形式的前列腺特异性抗原(PSA)和总PSA。该测定法基于时间分辨荧光,包括一种稳定的铕荧光螯合物,用于标记仅检测游离PSA的单克隆抗体(mAb),而用铽荧光螯合物标记的第二种mAb可等摩尔检测游离PSA和与α1-抗糜蛋白酶复合的PSA。固相上的第三种mAb以等摩尔方式捕获游离和复合形式的PSA。一步双测定法同时测量游离PSA与总PSA的比值(F/T)对样品体积的变化不敏感。在区分良性前列腺增生和前列腺癌患者时,即受试者操作特征曲线下的面积,当分别用单测定法和双测定法测量F/T比值时,从0.64(总PSA测定法)增加到0.78和0.81。